Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

Core Viewpoint - Aethlon Medical, Inc. has entered into a securities purchase agreement for a private placement to raise approximately $3.3 million through the sale of common stock and warrants, aimed at supporting its development of medical products for cancer and infectious diseases [1][3]. Group 1: Securities Purchase Agreement - The company will sell 595,897 shares of common stock and warrants to purchase up to 1,042,820 additional shares, with a combined effective offering price of $4.03 per share [1]. - The warrants will have an exercise price of $4.03 and will be exercisable upon shareholder approval, expiring five and a half years after such approval [1]. Group 2: Warrant Inducement Agreement - Aethlon has entered into a warrant inducement agreement to allow the investor to exercise certain outstanding warrants at a reduced price of $4.03, which includes 155,000 shares from March 2025 Warrants and 55,555 shares from September 2025 Warrants [2]. - In exchange for the immediate exercise of these warrants, the company will issue new unregistered warrants for an additional 368,471 shares, also at an exercise price of $4.03 [2]. Group 3: Financial Details - The gross proceeds from the private placement and warrant inducement are estimated to be around $3.3 million before deducting fees and expenses [3]. - The offering is expected to close on or about December 8, 2025, pending customary closing conditions [3]. Group 4: Company Overview - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases [6].